Abstract
Multiple sclerosis is a serious neurological disease that affects an estimated 20,000 patients in the Czech Republic. We are not yet able to cure the disease, the only effective prevention of irreversible disability is the timely initiation of anti-inflammatory therapy with continuous monitoring and adjustment of therapy according to individual activity of the disease.
Data from real clinical practice are crucial for evaluating the efficacy and safety of treatment. In the Czech Republic since 2013, the regular collection of this data has been ensured by the nationwide ReMuS register, the founder of which is the Endowment Fund Impuls in cooperation with the Czech Neurological society.
As of 31 December 2019, data from 16,300 patients were in the registry, of which 14,823 patients had at least 1 visit to the MS center during 2019. The article presents a selection of current data on demography, clinical parameters and treatment in the ReMuS registry